As of 2025-10-15, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -3.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 285.39 mil USD. ENTA's TTM EBITDA according to its financial statements is -93.04 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.4x - 14.0x | 11.0x |
| Forward P/E multiples | 10.4x - 15.9x | 12.2x |
| Fair Price | (30.67) - (42.02) | (34.67) |
| Upside | -379.9% - -483.4% | -416.4% |
| Date | EV/EBITDA |
| 2025-10-14 | -3.07 |
| 2025-10-13 | -3.24 |
| 2025-10-10 | -3.09 |
| 2025-10-09 | -3.23 |
| 2025-10-08 | -3.18 |
| 2025-10-07 | -3.11 |
| 2025-10-06 | -3.19 |
| 2025-10-03 | -2.86 |
| 2025-10-02 | -2.86 |
| 2025-10-01 | -2.95 |
| 2025-09-30 | -3.39 |
| 2025-09-29 | -4.42 |
| 2025-09-26 | -2.08 |
| 2025-09-25 | -2.03 |
| 2025-09-24 | -2.05 |
| 2025-09-23 | -1.85 |
| 2025-09-22 | -2.02 |
| 2025-09-19 | -2.00 |
| 2025-09-18 | -2.06 |
| 2025-09-17 | -1.96 |
| 2025-09-16 | -1.94 |
| 2025-09-15 | -1.94 |
| 2025-09-12 | -2.20 |
| 2025-09-11 | -2.33 |
| 2025-09-10 | -2.22 |
| 2025-09-09 | -2.45 |
| 2025-09-08 | -2.41 |
| 2025-09-05 | -2.39 |
| 2025-09-04 | -2.40 |
| 2025-09-03 | -2.38 |
| 2025-09-02 | -2.44 |
| 2025-08-29 | -2.24 |
| 2025-08-28 | -2.34 |
| 2025-08-27 | -2.28 |
| 2025-08-26 | -2.32 |
| 2025-08-25 | -2.33 |
| 2025-08-22 | -2.38 |
| 2025-08-21 | -2.30 |
| 2025-08-20 | -2.38 |
| 2025-08-19 | -2.24 |
| 2025-08-18 | -2.17 |
| 2025-08-15 | -2.11 |
| 2025-08-14 | -2.03 |
| 2025-08-13 | -1.98 |
| 2025-08-12 | -1.75 |
| 2025-08-11 | -1.63 |
| 2025-08-08 | -1.76 |
| 2025-08-07 | -1.79 |
| 2025-08-06 | -1.83 |
| 2025-08-05 | -1.92 |